↓ Skip to main content

RNA Vaccines

Overview of attention for book
Cover of 'RNA Vaccines'

Table of Contents

  1. Altmetric Badge
    Book Overview
  2. Altmetric Badge
    Chapter 1 Introduction to RNA Vaccines.
  3. Altmetric Badge
    Chapter 2 Self-Replicating RNA.
  4. Altmetric Badge
    Chapter 3 Self-Replicating RNA Vaccine Delivery to Dendritic Cells.
  5. Altmetric Badge
    Chapter 4 Plant Expression of Trans-Encapsidated Viral Nanoparticle Vaccines with Animal RNA Replicons.
  6. Altmetric Badge
    Chapter 5 RNActive® Technology: Generation and Testing of Stable and Immunogenic mRNA Vaccines.
  7. Altmetric Badge
    Chapter 6 Nucleoside Modified mRNA Vaccines for Infectious Diseases.
  8. Altmetric Badge
    Chapter 7 Generation and Evaluation of Prophylactic mRNA Vaccines Against Allergy.
  9. Altmetric Badge
    Chapter 8 Measuring the Adjuvant Activity of RNA Vaccines.
  10. Altmetric Badge
    Chapter 9 Generation of Immunostimulating 130 nm Protamine-RNA nanoparticles.
  11. Altmetric Badge
    Chapter 10 Electroporation of mRNA as Universal Technology Platform to Transfect a Variety of Primary Cells with Antigens and Functional Proteins.
  12. Altmetric Badge
    Chapter 11 Adjuvant-Enhanced mRNA Vaccines.
  13. Altmetric Badge
    Chapter 12 Enhanced Delivery of DNA or RNA Vaccines by Electroporation.
  14. Altmetric Badge
    Chapter 13 The European Regulatory Environment of RNA-Based Vaccines.
  15. Altmetric Badge
    Chapter 14 Discovery and Subtyping of Neo-Epitope Specific T-Cell Responses for Cancer Immunotherapy: Addressing the Mutanome.
  16. Altmetric Badge
    Chapter 15 Considerations for Producing mRNA Vaccines for Clinical Trials.
  17. Altmetric Badge
    Chapter 16 Nonclinical Safety Testing of RNA Vaccines.
  18. Altmetric Badge
    Chapter 17 Immunotherapy of Uveal Melanoma: Vaccination Against Cancer.
Attention for Chapter 13: The European Regulatory Environment of RNA-Based Vaccines.
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • Among the highest-scoring outputs from this source (#35 of 13,008)
  • High Attention Score compared to outputs of the same age (96th percentile)
  • High Attention Score compared to outputs of the same age and source (99th percentile)

Mentioned by

policy
1 policy source
twitter
74 tweeters
wikipedia
1 Wikipedia page
video
1 video uploader

Citations

dimensions_citation
10 Dimensions

Readers on

mendeley
56 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Chapter title
The European Regulatory Environment of RNA-Based Vaccines.
Chapter number 13
Book title
RNA Vaccines
Published in
Methods in molecular biology, January 2017
DOI 10.1007/978-1-4939-6481-9_13
Pubmed ID
Book ISBNs
978-1-4939-6479-6, 978-1-4939-6481-9
Authors

Thomas Hinz, Kajo Kallen, Cedrik M. Britten, Bruno Flamion, Ulrich Granzer, Axel Hoos, Christoph Huber, Samir Khleif, Sebastian Kreiter, Hans-Georg Rammensee, Ugur Sahin, Harpreet Singh-Jasuja, Özlem Türeci, Ulrich Kalinke, Hinz, Thomas, Kallen, Kajo, Britten, Cedrik M., Flamion, Bruno, Granzer, Ulrich, Hoos, Axel, Huber, Christoph, Khleif, Samir, Kreiter, Sebastian, Rammensee, Hans-Georg, Sahin, Ugur, Singh-Jasuja, Harpreet, Türeci, Özlem, Kalinke, Ulrich

Editors

Thomas Kramps, Knut Elbers

Abstract

A variety of different mRNA-based drugs are currently in development. This became possible, since major breakthroughs in RNA research during the last decades allowed impressive improvements of translation, stability and delivery of mRNA. This article focuses on antigen-encoding RNA-based vaccines that are either directed against tumors or pathogens. mRNA-encoded vaccines are developed both for preventive or therapeutic purposes. Most mRNA-based vaccines are directly administered to patients. Alternatively, primary autologous cells from cancer patients are modified ex vivo by the use of mRNA and then are adoptively transferred to patients. In the EU no regulatory guidelines presently exist that specifically address mRNA-based vaccines. The existing regulatory framework, however, clearly defines that mRNA-based vaccines in most cases have to be centrally approved. Interestingly, depending on whether RNA-based vaccines are directed against tumors or infectious disease, they are formally considered gene therapy products or not, respectively. Besides an overview on the current clinical use of mRNA vaccines in various therapeutic areas a detailed discussion of the current regulatory situation is provided and regulatory perspectives are discussed.

Twitter Demographics

The data shown below were collected from the profiles of 74 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 56 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 56 100%

Demographic breakdown

Readers by professional status Count As %
Student > Master 10 18%
Student > Ph. D. Student 8 14%
Researcher 7 13%
Student > Bachelor 6 11%
Professor 4 7%
Other 5 9%
Unknown 16 29%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 5 9%
Agricultural and Biological Sciences 5 9%
Medicine and Dentistry 5 9%
Pharmacology, Toxicology and Pharmaceutical Science 5 9%
Immunology and Microbiology 3 5%
Other 12 21%
Unknown 21 38%

Attention Score in Context

This research output has an Altmetric Attention Score of 59. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 25 November 2022.
All research outputs
#599,317
of 22,608,005 outputs
Outputs from Methods in molecular biology
#35
of 13,008 outputs
Outputs of similar age
#15,412
of 424,743 outputs
Outputs of similar age from Methods in molecular biology
#3
of 1,655 outputs
Altmetric has tracked 22,608,005 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 97th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 13,008 research outputs from this source. They receive a mean Attention Score of 3.3. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 424,743 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 96% of its contemporaries.
We're also able to compare this research output to 1,655 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 99% of its contemporaries.